Isosulfan blue 1% vial 5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSCA5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,293
Award facts
- Contract value 100% obligated
- $22,292.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $22,292.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Isosulfan Blue 1% vial (5mL). The delivery order, issued on December 4, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR and valued at $499,999,999 through December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to support recurring pharmaceutical and medical supply requirements for Department of Defense healthcare facilities worldwide.
Isosulfan Blue is a vital injectable dye utilized in surgical procedures for lymphatic mapping and sentinel lymph node identification during cancer surgeries and other operative interventions. As a prime vendor under the PPV-G GEN V program, DMS Pharmaceutical Group supplies an extensive portfolio of pharmaceuticals including oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables to military healthcare installations globally. The company's substantial federal contracting activity and established performance across multiple delivery orders demonstrate its operational capability to fulfill the specialized pharmaceutical requirements of the Department of Defense medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FSCA5?
SPE2DR26FSCA5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FSCA5 worth?
The government has obligated $22,293 on SPE2DR26FSCA5.
Is contract SPE2DR26FSCA5 an order under another contract?
Yes. SPE2DR26FSCA5 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCA5 competed?
The extent of competition for SPE2DR26FSCA5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award